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Abstract
Arachidonic acid (AA) is known to be increased in HIV infected patients and illicit drug users are linked with severity of viral
replication, disease progression, and impaired immune functions. Studies have shown that cocaine accelerates HIV infection
and disease progression mediated by immune cells. Dendritic cells (DC) are the first line of antigen presentation and
defense against immune dysfunction. However, the role of cocaine use in HIV associated acceleration of AA secretion and its
metabolites on immature dendritic cells (IDC) has not been elucidated yet. The aim of this study is to elucidate the
mechanism of AA metabolites cyclooxygenase-2 (COX-2), prostaglandin E2 synthetase (PGE2), thromboxane A2 receptor
(TBXA2R), cyclopentenone prostaglandins (CyPG), such as 15-deoxy-D12,14-PGJ2 (15d-PGJ2), 14-3-3 f/d and 5-lipoxygenase
(5-LOX) mediated induction of IDC immune dysfunctions in cocaine using HIV positive patients. The plasma levels of AA,
PGE2, 15d-PGJ2, 14-3-3 f/d and IDC intracellular COX-2 and 5-LOX expression were assessed in cocaine users, HIV positive
patients, HIV positive cocaine users and normal subjects. Results showed that plasma concentration levels of AA, PGE2 and
COX-2, TBXA2R and 5-LOX in IDCs of HIV positive cocaine users were significantly higher whereas 15d-PGJ2 and 14-3-3 f/d
were significantly reduced compared to either HIV positive subjects or cocaine users alone. This report demonstrates that
AA metabolites are capable of mediating the accelerative effects of cocaine on HIV infection and disease progression.
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Introduction
During the last decade, an intertwined epidemic of drug abuse
and HIV-1 infections has emerged. Globally there were an
estimated 34.2 million people living with HIV [1]. Illicit drug
abuse including cocaine is a significant risk factor for HIV
infection and AIDS disease progression [2,3]. Cocaine is currently
being used worldwide in epidemic proportions, particularly in the
U.S. The 2010 report shows that 1.5 million Americans (aged 12
or older) are cocaine users [4]. Overall, about 16 million injecting
drug users are present worldwide and 3 million (18.9 per cent) of
them are living with HIV [1]. Previous studies suggest that cocaine
use and HIV-1 infection are independently associated with
immune dysfunction which leads to neuronal impairments [5,6].
Dendritic cells (DC) play a significant role as the first line of
defense against viral pathogens and illicit drug effects [7,8]. HIV-1
directly affects dendritic cells (DC) and leads to dysfunction of
immune system manifested by increased levels of inflammatory
cytokines, chemokines and neurotoxin such as quinolinic acid and
arachidonic acid (AA) [9,10]. Increasing evidence suggests that
DCs play a major role in the defense against HIV infection and
illicit drug such as cocaine [11–13]. Immature dendritic cells (IDC)
specialize in capturing and processing antigens and plays wide role
in cell maturation, migration to CD4+ T cells, and T cell
activation [14]. Previous studies indicate that AA metabolites such
as COX-2, TBXA2, 5-LOX and 15d-PGJ2 found in specific DC
subsets interplay with immune regulation [15,16]. Also, AA
metabolites COX-2 induce T-cell tolerance to antigenic stimuli
which could affect immune functions [17]. Indeed, expression of
COX-2 activation subsequently affect via TBXA2, 15d-PGJ2 and
5-LOX which are the potential markers of viral replication as well
as immune and neuronal impairments [18,19]. However, the
COX-2 and 5-LOX can be regulated via monocytes and dendritic
cells through activation of T cells signaling during inflammatory
processes [20]. Furthermore, the 5-LOX enzyme plays an
important role in leukotriene B4, a potent inflammatory mediator
in peripheral disorders [21], and neurotoxicity [22]. The members
of the PGJ2 class, 15d-PGJ2 (also called cyclopentenone PGs,
CyPG), play a role in checkpoint of cytokine/chemokine synthesis
and intracellular translocation of HIV viral protein and viral
replication [23]. 15d-PGJ2 has anti-inflammatory properties [24],
and it negatively regulates PGE2 synthetase. However, increased
levels of AA directly bind with 14-3-3 f/d protein polymerization
and affect their cellular function [25]. Furthermore, decreased 14-
3-3 f/d proteins subsequently affect platelet aggregation mediated
by platelet activating factor (PAF), which may induce apoptosis.
Studies have consistently demonstrated that cocaine use and
HIV infection accelerates viral replication, disease progression
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which leads susceptibility and severity of immune dysfunction
[3,25] which leads to HIV-associated neurocognitive disorder
(HAND) [26]. HIV positive cocaine user’s exhibit accelerated
disease progression compared to non- cocaine using HIV positive
individuals [2, 3. 26, 27]. Our recent report demonstrated that
HIV derived gene product gp120 with cocaine interaction
potentiated the additive effect of AA metabolite COX-2 induction
in primary astrocytes [28]. Despite mounting evidence which
suggests that cocaine use may exacerbate HIV disease, mechanis-
tic studies assessing the interactive role of cocaine and HIV
infection on DC and their role remains to be determined.
In this study, we investigated the role of AA metabolites COX-
2, PGE2, 15d-PGJ2, 14-3-3 f/d, TBXA2R, and 5-LOX associated
immunopathogenesis in HIV positive cocaine users. We showed
that cocaine use in HIV positive subjects enhances immune
dysfunction and exacerbates the neurotoxin AA metabolites gene,
protein and intracellular expression in IDC.
Methods and Materials
Human subjects
Blood donors were recruited from the Borinquen Health Care
Center, Inc., Miami. Written and signed consent forms were
obtained from all participants in compliance with Florida
International University (FIU) and the National Institutes of
Health (NIH) policies. All participants consent forms are kept in a
lock cabinet to maintain confidentiality. The protocol was
approved by the IRB of FIU. Peripheral blood from normal,
HIV positives, cocaine users and HIV-1 positive cocaine users was
drawn into heparin lined tubes (20cc). Human subjects were
recruited through collaborating physicians, community agencies,
as well as by participant referral. After eligibility was confirmed,
informed consents were obtained. Participants provided medical
documentation to confirm HIV and Hepatitis B and C status. For
HIV positive individuals, medical documentation confirmed CD4
and Viral loads. Individuals younger than 18 years old and with
Hepatitis B and/or Hepatitis C infection were deemed ineligible.
Self-report data was collected concerning drug use history, and
participant’s blood specimens were collected by a Registered
Nurse.
HIV-infected and control populations
HIV-1 infection are defined as individuals who exhibit a faster
decline in CD4 lymphocytes, displaying a declining slope of .50
CD4 T cells per cubic millimeter per semester and an overall CD4
loss .30% with a current CD4 count ,500 and plasma viral load
.50,000 copies/ml. However, in the present study, overall
patients were taking more than two antiretroviral drugs and the
patients taking ART showed increase in CD4 significantly. The
number of normal subjects, cocaine user, HIV positive and HIV
positive cocaine user average age and CD4 counts are given in
Table 1. Cocaine use with/without HIV were confirmed by urine
toxicology testing on the day of blood collection. Control or
normal groups (drug free and HIV negative) were healthy
volunteers who were age-, sex-, and ethnically matched with
HIV-1-infected subjects and cocaine users. A clinical history was
obtained from all normal donors. However, in this study only
cocaine user and HIV positive cocaine users were recruited.
Exclusion criteria for all groups were age ,18 and .50 years,
pregnancy, Hepatitis B and C (Table 1).
Isolation and generation of immature DC (IDC)
DCs were prepared from PBMC as described [2]. Blood
samples from normal, cocaine users, HIV positive and HIV
positive cocaine users were collected and Peripheral Blood
Mononuclear Cells (PBMC) were separated on a density gradient
and adhered to plastic culture plates in serum containing medium.
Non adherent cells were removed after 1 h at 37uC, and adherent
cells were cultured for 6 days in medium containing 100 U/ml
recombinant human GM-CSF and 100 U/ml IL-4 (R&D
Systems). After 6 days of culture, iDC were removed by gently
swirling the plate to resuspend them for use in the experiments.
IDC were washed in FACS buffer (eBioscience), incubated with
nonspecific IgG (20 mg/ml) for 10 min at 4uC to block FcR,
stained with specific Abs for DC surface markers, and analyzed by
flow cytometry. The IDC express CD80, CD86, CD40, HLA-DR,
DQ, and CD11c at different levels.
RNA Extraction and Real time quantitative PCR (qRT-PCR)
Total RNA from IDC was extracted using the Qiagen kit
(Invitrogen Life Technologies, Carlsbad, CA, USA) following the
manufacturer’s instructions. The total RNA (3 mg) was used for the
synthesis of the first strand of cDNA. The amplification of cDNA
was performed and using specific primers for COX-2 (Assay ID,
Hs00153133), TBXA2 R (Assay ID, Hs00169054), 5-LOX (Assay
ID Hs00386528), and b-actin (Assay ID, Hs99999903) (Applied
Biosystems, Foster City, CA) was used as housekeeping gene for
quantifying real-time PCR. Relative abundance of each mRNA
species was assessed using brilliant Q-PCR master mix from
Stratagene using Mx3000P instrument which detects and plots the
increase in fluorescence versus PCR cycle number to produce a
continuous measure of PCR amplification. Relative mRNA
species expression was quantitated and the mean fold change in
expression of the target gene was calculated using the comparative
CT method (Transcript Accumulation Index, TAI = 22DDCT). All
data were controlled for quantity of RNA input by performing
measurements on an endogenous reference gene, b-actin. In
addition, results on RNA from treated samples were normalized to
results obtained on RNA from the control, untreated sample.
Quantification of PGE2 and 15d-PGJ2 by enzyme- linked
immunosorbent assay (ELISA)
Plasma were separated from normal, cocaine users, HIV
positive patients, and cocaine using HIV positive subjects as
previously mentioned. Plasma was analyzed for PGE2 (GenWay
Biotech Inc. San Diego, CA) and 15d-PGJ2 (Enzo Life Sciences,
Farmingdale, NY) using commercially available ELISA kits as per
the manufacturer’s instructions.
Level of neurotoxin AA in plasma by GC/MS
Blood samples were centrifuged at 2400 g for 10 min at 4uC.
Aliquots (1 mL) of plasma were transferred to Eppendorf tubes
and were stored at –70uC until analysis. Plasma 50 ml was
hydrolyzed in the presence of 1 mol/L potassium hydroxide at
40uC for 30 min. 50 mL of distilled water, 3 mL of concentrated
hydrochloric acid, 200 mL of ice-cold Folch solution (chloroform–
methanol, 2:1 by volume), and 50 ng of AA-d8 (internal standard)
were added to 50 mL of hydrolyzed sample. After thorough vortex-
mixing, the sample was centrifuged at 2400 g for 5 min. The
lower organic layer was transferred to another Eppendorf tube and
evaporated under nitrogen. The residue was then dissolved in
100 mL distilled water, and AA was extracted by the addition of
100 mL of hexane. The hexane extracts were dried under nitrogen
and AA was analyzed by GC/MS, according to the modified
method of Hadley et al [29].
Cocaine Accelerates HIV Disease Progression
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Analysis of intracellular expression of COX-2 and 5-LOX in
IDC
Cocaine and HIV induced intracellular COX-2 and 5-LOX
expressions were analyzed by flow cytometry in FACS caliber (BD
Bioscience, San Jose, CA). Briefly, IDC (56105) were separated
from normal, cocaine users, HIV positive patients, and HIV
positive with cocaine user’s subjects. Cells were harvested and
washed twice with PBS. The cells were fixed and permeabilized by
Cytofix/Cytoperm Kit (BD Pharmingen, San Diego, CA, USA)
following the manufacturer’s instructions. Cells were incubated
with anti-COX2 (FITC) and anti-5 LOX (FITC) (antibodies-
online, Atlanta, USA) for 20 min at 4u than washing with PBS and
analyzed intracellular COX-2 and 5-LOX expression.
Western blot analysis
To determine the COX-2, TBXA2 R and 5-LOX protein
modification in IDC and serum 14-3-3 f/d protein levels in
normal, cocaine users, HIV positive and cocaine using HIV
positive subjects. Equal amount of total cellular protein were
resolved on a 4–15% gradient polyacrylamide gel electrophoresis,
transferred to a nitrocellulose membrane and incubated with their
respective primary antibodies. Immunoreactive bands were
visualized using a chemiluminescence western blotting system
according to the manufacturers’ instructions (Amersham Piscat-
away, NJ, USA).
Data analysis
In general total of 60 samples were utilized for the experiments.
However, some of the experiments as indicated in the figures at
least six samples were utilized in each group. The values obtained
were averaged and data are represented as the mean 6 standard
error. All the data were analyzed using GraphPad Prism- software
version 5. Comparisons between groups were performed using
one-way ANOVA and differences were considered significant at
p#0.05 and we performed post- test using ‘‘t’’ test.
Results
Demographics of Cohort
A total of 60 subjects were utilized for the study. The groups
were as follows: 12-control (normal) subjects, 12- cocaine users, 19-
HIV positive subjects and 18- HIV positive subjects with long-
standing history of cocaine use. The groups of patients and control
subjects were similar in age with male predominance.
Cocaine increases HIV-1induced AA metabolites in IDC
Studies have shown that HIV positive subjects who have used
illicit drugs are more sensitive to immune-neuropathogenesis than
either substance abusers or HIV positive subjects [26,30]. In this
study, we have investigated the possible role of cocaine increasing
HIV induced AA and its metabolites COX-2, TBXA2 and 5-LOX
in IDC. Data presented in Fig. 1A show IDC from cocaine users
(p,0.03), HIV positive patients (p,0.03) and cocaine users with
HIV positive subjects (p,0.003) significantly upregulated COX-2
gene expression compared to normal subjects. Fig. 1B shows a
significant increase in TBXA2 gene expression cocaine users (p,
0.01), HIV positive (p,0.007) and cocaine user with HIV positive
subjects (p,0.03) compared with normal subjects. To examine
whether AA metabolites of 5-LOX expression are similar or
different from COX-2 expression, we performed expression
profiles of 5-LOX. Fig. 1C results indicate that in cocaine users
(p,0.04), HIV positives (p,0.02) and cocaine users with HIV
positive subjects (p,0.002) have significantly higher levels of 5-
LOX gene expression, compared to normal subjects.
Cocaine impact of AA metabolites PGE2 and 15d-PGJ2 in
HIV-infected Plasma
Our previous report demonstrated that AA metabolites
potentiated additive effect of gp120 with cocaine [28]. Therefore,
in this study we also examined the level of AA, metabolites PGE2
and 15d-PGJ2 in cocaine users, HIV positives and cocaine users
with HIV positives subjects. Data presented in Fig. 2A show that
cocaine users have increased levels of AA but not significant;
however, HIV positive (p,0.02) and cocaine users with HIV
positives (p,0.002) have significantly increased higher levels of AA
compared to normal subjects. The level of PGE2 in cocaine users
and HIV positive cocaine users shows a significant increase when
compared to controls. The data in Fig. 2B show the level of PGE2
respectively in HIV positive subjects (p,0.0001), cocaine user (p,
0.0001) and cocaine users with HIV positive subjects (p,0.0001).
Cocaine and HIV infection is synergistic as evidenced by
significantly increased PGE2 (p,0.0001) when compared to either
HIV positive (p,0.0001) or cocaine use alone (p,0.0001). In
addition, the AA metabolite of anti-inflammatory 15d-PGJ2 is the
major player in controlling the onset and resolution of acute
inflammation. Since no studies have reported on the quantification
of 15d-PGJ2 in HIV infected drug abusers. Fig. 2C indicated that
the level of 15d-PGJ2 in HIV positives cocaine users shows a
significant decrease (P,0.02) when compared to either cocaine or
HIV positive (P,0.02) subjects. In the analysis of present data
using in ANOVA the values were significantly less than p,0.001
and accordingly suggest the synergistic effects in the anti-
inflammatory response which leads to increased AA metabolites
in HIV positive cocaine users.
Cocaine accelerates intracellular expression of COX-2 and
5-LOX
Since increased AA levels might results in modulation of
intracellular levels of COX-2 and 5-LOX, and these two
important enzymes are metabolized polyunsaturated fatty acids
that function as parallel pathways on AA metabolism, we analyzed
intra cellular expression levels of COX-2 and 5-LOX by flow
cytometry. Data presented in Fig. 3 shows COX-2 expression in
cocaine user (12%), HIV positive (14%) and HIV positive with
Table 1. Baseline characteristics of HIV positive subjects with cocaine user.
Normal Subjects Cocaine User HIV Positive HIV Positive Cocaine user
Age 32.4666.22 41.5263.81 36.1463.75 44.5764.63
Sex Male –9 Female – 3 Male –6 Female – 6 Male –11 Female - 8 Male –9 Female – 9
CD4 – – $466/ml $308/ml
doi:10.1371/journal.pone.0106348.t001
Cocaine Accelerates HIV Disease Progression
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cocaine users (27%) compared with control. Fig. 4 demonstrated
that 5-LOX expression significantly increased in HIV positive
cocaine users (41%) in comparison with either cocaine users (13%)
or HIV positive subjects (17%) alone. These results suggest that
HIV positive cocaine users have higher levels of AA and
metabolites of COX-2 and 5-LOX expression.
Cocaine exacerbates HIV-induced protein modification in
IDC
In order to understand protein expression mimics similar to
gene expression in AA metabolites in HIV positive cocaine users.
Therefore, we also analyzed COX-2, TBXA2 R, 5-LOX and 14-
3-3 f/d protein expression in terms of cocaine users, HIV infected
Figure 1. Effect of arachidonic acid metabolites COX-2, TBXA2 R and 5-LOX gene expression. IDC (36106 cells/ml) were isolated from
normal, cocaine users, HIV positives and HIV positive cocaine users. RNA was extracted and reverse transcribed followed by quantitative real time PCR
for COX-2 (A), TBXA2 R (B), 5-LOX (C), and housekeeping b-actin specific primers. Data are expressed as mean 6 SD of TAI values of six independent
human samples.
doi:10.1371/journal.pone.0106348.g001
Figure 2. The level of AA, PGE2 and 15d-PGJ2 in cocaine users and HIV infected subjects. The plasma was separated and analyzed AA by
GC/MS, PGE2 and 15d-PGJ2 level by ELISA in normal, cocaine users, HIV positives, and HIV positive cocaine users. Data are expressed as % fold change
of AA (A), and ng/ml plasma (B and C).
doi:10.1371/journal.pone.0106348.g002
Cocaine Accelerates HIV Disease Progression
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subjects and cocaine using HIV infected patients in IDC. Fig. 5
demonstrates that COX-2 (A), TBXA2 R (B) and 5-LOX (C)
protein is significantly up regulated whereas 14-3-3 f/d (D)
significantly reduced by cocaine users, HIV positive subjects and
HIV positive with cocaine users. These observed results are
consistent with cocaine using HIV infected patients levels of AA
and metabolites PGE2 and 15d-PGJ2. Data presented in Fig. 5 E,
F, G and H show the densitometry evaluation respectively COX-2
(p,0.009), TBXA2 R (p,0.009), 5-LOX (p,0.004) and 14-3-3 f/
d (p,0.007). These results confirm increased level of AA, PGE2
and COX-2 expression subsequently decreased anti-inflammatory
level of 15d-PGJ2 and 14-3-3 f/d protein inhibition in cocaine
users, HIV positive subjects and HIV positive cocaine users when
compared with normal subjects.
Discussion
Previous studies have shown that AA and its metabolites play a
wide role in immune dysfunction, behavioral impairments as well
as viral replication and disease progression in HIV-infection and
substance abuse [9,18,23]. The increasing AA metabolites COX-2
and 5-LOX are associated with HAD or HAND. COX-2 enzyme
is an important player in the regulation of immune functions (e.g.
immune tolerance) of antigen-presenting cells such as macrophag-
es or DC [31,32]. An increase in AA secretion by HIV infection
and their metabolites COX-2, PGE2, TBXA2 and 5-LOX are
found in cerebrospinal fluid (CSF) of HAD-patients [33–35].
However, overstimulation of AA leads to increase in its metabolites
COX-2 and PGE2 [36,37], and subsequently decreased the level
of 15d-PGJ2 and 14-3-3 f/d, which may play a vital role in
immune dysfunction and disease progression [38,39] in HAD
patients [26]. The DC differentiation, maturation, migration, and
antigen presentation function are modulated by COX-2 induced
prostaglandins (PGs) [15,40,41]. However, there are no reports on
the impact of cocaine on AA metabolites in HIV positive cocaine
users. The present study provides new insights into the functional
role of COX-2 in AA metabolites TBXA2 which subsequently
affects 5-LOX in HIV infection and cocaine use. Our previous
in vitro study has shown that the HIV-1 gp120 protein induces the
COX-2 mRNA expression and protein modification implicated in
neuro-AIDS [42].
Figure 3. Effect of intracellular COX-2 expression in cocaine users and HIV infected patients. IDC (56105 cells/ml) were isolated from
normal, cocaine users, HIV positive and HIV positive cocaine user intracellular expression of COX-2 (A) and % COX-2 positive cells (B) was analyzed by
flow cytometry. Data are expressed and represented as mean 6 SD of six independent experiments.
doi:10.1371/journal.pone.0106348.g003
Figure 4. Effect of intracellular 5-LOX expression in cocaine users and HIV infected patients. IDC (56105 cells/ml) were isolated from
normal, cocaine users, HIV positives and HIV positive cocaine users intracellular expression of 5-LOX (A) and % 5-LOX positive cells (B) was analyzed
by flow cytometry. Data are expressed and represented as mean6 SD of six independent experiments.
doi:10.1371/journal.pone.0106348.g004
Cocaine Accelerates HIV Disease Progression
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In the present study, we have demonstrated for the first time
that cocaine users, HIV positive and HIV positive cocaine users
have increased levels of AA and mRNA expression of metabolites
COX-2, TBXA2, 5-LOX (Fig. 1), and the levels of AA and PGE2
(Fig. 2) are associated with reduction in 15d-PGJ2 compared to
normal subjects. It is known that AA metabolites PGE2, COX-2,
TBXA2 and 5-LOX are the major players in immune dysfunction
[43–45], and reduced level of 15d-PGJ2 and 14-3-3 f/d, may
enhance viral replication and disease progression. These studies
suggest that cocaine abusing HIV positive subjects may have an
enhanced role of COX-2 and AA metabolites compared to normal
subjects. This is consistent with earlier reports of gp120 induced
neuroblastoma cells and HIV infected pulmonary hypertension,
where activation of the COX-2 and 5-LOX pathways has been
observed [36,46]. Also, studies have shown that suicidal behavioral
impairments are associated with 5-LOX increased in cerebral
cortex brain regions [47]. These studies further confirm that the
downstream effect of TBXA2 and 5-LOX are upregulated in
cocaine using HIV positive subjects leading to depression and
suicidal behavior. However, TBXA2 is an unstable product which
initiates the PAF, blood aggregation induction and subsequently
increases TBX B, which may be mediated by 14-3-3 f/d leading
to immune and neuronal impairments. Supporting our hypothesis,
recent studies have demonstrated that 14-3-3 f/d protein play a
wide role in cytoskeletal translocation and platelet dysfunctions
[48]. These results confirm that increased AA metabolites
exacerbate the immune dysfunction in cocaine abusing HIV
infected subjects.
Further, our results show that in cocaine users, HIV infected
subjects, and cocaine using HIV infected subjects induction of
intracellular COX-2 and 5-LOX expression (Fig. 3 and 4) is
associated with a concomitant activation of COX-2 and 5-LOX
protein (Fig. 5). The main observation in this report is that HIV
positive and cocaine using HIV positive subjects have higher levels
of PGE2 due to secretion of AA and COX-2 activation and
subsequently reducing the level of 15d-PGJ2 and 14-3-3 f/d.
However, HIV positive cocaine users have higher levels of AA and
metabolites. This suggests that HIV positive cocaine synergistically
potentiate disease progressive effect when compared to either
cocaine use or HIV positive alone.
Previous studies indicate that AA metabolites affect monocytes
in HIV positive drug users [33] and HIV-1 envelop protein gp120
induced viral replication subsequently affect the immune function
in human DCs [40]. In the present study, IDC in cocaine using
HIV infected subjects showed an increased level of AA metabolites
COX-2, TBXA2 R and 5-LOX gene expression and protein
modification with significant increase of PGE2 levels compared to
normal subjects. Also, increased functional COX-2 enzyme
activity in DC could lead to an enhanced production of neurotoxin
AA [49], which alters immune tolerance and causes imbalance
resulting in immuno-neuropathogenesis [50]. These results suggest
that IDC play a role in protective mechanisms of immune
function, during HIV infection and cocaine abuse since both can
alter AA levels and subsequently accelerate disease progression
mediated by COX-2 and 5-LOX.
Overall, the data provide evidence of an interaction of cocaine
use and HIV infection leading to an association between AA and
its metabolites COX-2, TBXA2 R and 5-LOX by increasing the
levels of PGE2, and formation of neurotoxin AA subsequently
reducing the levels of 15d-PGJ2 and 14-3-3 f/d in HIV positive
cocaine users. Based on these results, AA and its metabolites
Figure 5. Effect of arachidonic acid metabolites COX-2, TBXA2 R and 5-LOX protein expression in IDC and 14-3-3 d/f in plasma were
isolated from normal, cocaine user, HIV positives and HIV positive cocaine users. Equal amount of IDC cell lysate and plasma protein were
resolved by 4–15% SDS-PAGE and protein expression were analyzed by Western blot showing COX-2 (A), TBXA2 R (B), 5-LOX (C) and 14-3-3 d/f (D).
Figure E, F, G and H represented % densitometric values of COX-2, TBXA2 R, 5-LOX and 14-3-3 d/f protein levels (% control). Data are expressed as
mean 6 SD of three independent experiments.
doi:10.1371/journal.pone.0106348.g005
Cocaine Accelerates HIV Disease Progression
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potentiate the HIV disease progression by impairing the possible
immune function [3,26,27,51].
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